OMERS ADMINISTRATION Corp Increases Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

OMERS ADMINISTRATION Corp lifted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 637.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 159,535 shares of the company's stock after purchasing an additional 137,888 shares during the period. OMERS ADMINISTRATION Corp's holdings in Dr. Reddy's Laboratories were worth $2,519,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. AIA Group Ltd increased its position in Dr. Reddy's Laboratories by 441.7% in the 4th quarter. AIA Group Ltd now owns 145,150 shares of the company's stock worth $2,292,000 after buying an additional 118,357 shares during the period. Vanguard Group Inc. increased its position in Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after acquiring an additional 3,911,404 shares during the period. Robeco Institutional Asset Management B.V. raised its stake in Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Dr. Reddy's Laboratories by 609.4% in the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company's stock valued at $92,000 after purchasing an additional 5,015 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Dr. Reddy's Laboratories by 400.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company's stock valued at $8,373,000 after purchasing an additional 427,573 shares during the period. 3.85% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Stock Performance

Shares of NYSE:RDY traded up $0.02 during trading on Tuesday, hitting $14.48. 384,911 shares of the stock were exchanged, compared to its average volume of 1,486,171. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of 23.05 and a beta of 0.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. Dr. Reddy's Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The company's fifty day simple moving average is $13.47 and its 200-day simple moving average is $14.03.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million for the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Sell-side analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.